GenCore version 5.1.6

OM protein - protein search, using sw model

Run on: August 22, 2003, 14:41:28 ; Search time 90 Seconds
(without alignments)
617.270 Million cell updates/sec

Title: US-09-745-506-37
Perfect score: 1799
Sequence: 1 MDLKALLSSLNDFASLSFAE.....LENKINIILSETDRDPLQVV 350

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 1107863 seqs, 158726573 residues

Total number of hits satisfying chosen parameters: 1107863

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : A_Geneseq_19Jun03:*
1: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1980.DAT:*
2: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1981.DAT:*
3: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1982.DAT:*
4: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1983.DAT:*
5: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1984.DAT:*
6: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1985.DAT:*
7: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1986.DAT:*
8: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1987.DAT:*
9: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1988.DAT:*
10: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1989.DAT:*
11: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1990.DAT:*
12: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1991.DAT:*
13: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1992.DAT:*
14: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1993.DAT:*
15: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1994.DAT:*
16: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1995.DAT:*
17: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1996.DAT:*
18: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1997.DAT:*
19: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1998.DAT:*
20: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1999.DAT:*
21: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA2000.DAT:*
22: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA2001.DAT:*
23: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA2002.DAT:*
24: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA2003.DAT:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	% Query Match	Length	DB	ID	Description
1	1799	100.0	350	22	AAG81361	Human AFP protein
2	1799	100.0	350	22	AAB94573	Human protein sequ
3	1799	100.0	383	22	AAM88085	Human immune/haema
4	1793	99.7	377	22	AAU27744	Human full-length
5	1743.5	96.9	351	22	AAB60663	Human gene express
6	1097	61.0	247	23	ABB08182	Human protein kina
7	578	32.1	288	22	ABB60530	Drosophila melanog
8	536	29.8	146	22	AAU27916	Human contig polyp
9	508	28.2	110	22	ABG20985	Novel human diagno
10	366	20.3	68	22	ABG52473	Human liver peptid
11	366	20.3	68	22	ABB32385	Peptide #5036 enco
12	366	20.3	68	22	ABB37667	Peptide #5173 enco
13	366	20.3	68	22	AAM58295	Human brain expres
14	366	20.3	68	22	AAM18609	Peptide #5043 enco
15	366	20.3	68	22	AAM06178	Peptide #4860 enco
16	330	18.3	79	22	AAU21467	Human novel foetal
17	305	17.0	367	23	ABP38833	Staphylococcus epi
18	296	16.5	360	22	AAG82528	S. epidermidis ope
19	280.5	15.6	403	22	AAU54649	Propionibacterium
20	249	13.8	376	22	AAG82506	S. epidermidis ope
21	240	13.3	373	23	ABB47970	Listeria monocytog
22	230	12.8	380	22	AAG92198	C glutamicum prote
23	230	12.8	380	22	AAB79495	Corynebacterium gl
24	216.5	12.0	379	24	ABP57497	Mycobacterium tube
25	210	11.7	264	23	ABP26738	Streptococcus poly
26	203.5	11.3	265	24	ABU02074	S. pneumoniae type
27	202	11.2	70	22	ABG20982	Novel human diagno
28	187.5	10.4	256	23	ABB54389	Lactococcus lactis
29	174	9.7	262	23	ABP30359	Streptococcus poly
30	174	9.7	263	23	ABP26737	Streptococcus poly
31	157.5	8.8	244	22	AAG81950	S. epidermidis ope
32	142	7.9	74	22	ABG20984	Novel human diagno
33	109.5	6.1	316	23	AAM49408	Escherichia coli r
34	103.5	5.8	733	22	AAU18289	Human endocrine po
35	101	5.6	673	20	AAW93593	Human kidney amino
36	101	5.6	673	23	ABG76981	Human aminopeptida
37	101	5.6	673	23	ABG76982	Human aminopeptida
38	101	5.6	673	23	ABG77025	Human aminopeptida
39	101	5.6	673	23	ABG77030	Human aminopeptida
40	101	5.6	674	24	ABP71024	Human membrane-bou
41	100	5.6	249	24	ABU06075	N. meningitidis va
42	98	5.4	257	24	ABP77069	N. gonorrhoeae ami
43	97	5.4	253	22	AAB96521	Putative P. abyssi
44	97	5.4	488	19	AAW98732	H. pylori GHPO 921
45	97	5.4	488	22	AAU35851	Helicobacter pylor

ALIGNMENTS

RESULT 1
AAG81361
ID AAG81361 standard; Protein; 350 AA.
XX
AC AAG81361;
XX
DT 10-SEP-2001 (first entry)
XX
DE Human AFP protein sequence SEQ ID NO:240.
XX
KW Human; secreted protein; secretion; bacterial cell; fungal cell;
KW eukaryotic cell; fusion protein; maltose binding protein;
KW immunoglobulin constant region; polyhistidine tag.
XX
OS Homo sapiens.
XX
PN WO200129221-A2.
XX
PD 26-APR-2001.
XX
PF 20-OCT-2000; 2000WO-US29052.
XX
PR 20-OCT-1999; 99US-0160712.
XX
PA (ZYMO) ZYMOGENETICS INC.
XX
PI Conklin DC, Yee DP;
XX
DR WPI; 2001-300340/31.
DR N-PSDB; AAH52212.
XX
PT Isolated polypeptide for directing secretion of proteins of interest

PT from a host cell including, e.g. bacteria, includes contiguous amino
PT acid residues of polypeptide with specified amino acids -
XX
PS Claim 1; Page 424-425; 617pp; English.
XX
CC AAH52093 to AAH52303 encode the human secreted proteins given in AAG81242
CC to AAG81453. The secreted proteins can be used for directing the
CC secretion of proteins of interest from a host cell including bacteria,
CC fungal cells, and cultured higher eukaryotic cells. The present invention
CC also describes fusion proteins, where a secreted protein of the invention
CC is operably linked via a peptide bond or peptide linker to a second
CC protein selected from the group consisting of maltose binding protein,
CC an immunoglobulin constant region, a polyhistidine tag and a peptide
CC given in AAG81453.
XX
SQ Sequence 350 AA;

Query Match 100.0%; Score 1799; DB 22; Length 350;
Best Local Similarity 100.0%; Pred. No. 1.4e-166;
Matches 350; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MDLKALLSSLNDFASLSFAESWDNVGLLVEPSPPHTVNTLFLTNDLTEEVMEEVLQKKAD 60
Db 1 MDLKALLSSLNDFASLSFAESWDNVGLLVEPSPPHTVNTLFLTNDLTEEVMEEVLQKKAD 60

Qy 61 LILSYHPPIFRPMKRITWNTWKERLVIRALENRVGIYSPHTAYDAAPQGVNNWLAKGLGA 120
Db 61 LILSYHPPIFRPMKRITWNTWKERLVIRALENRVGIYSPHTAYDAAPQGVNNWLAKGLGA 120

Qy 121 CTSRPIHPSKAPNYPTEGNHRVEFNVNYTQDLDKVMSAVKGIDGVSVTSFSARTGNEEQT 180
Db 121 CTSRPIHPSKAPNYPTEGNHRVEFNVNYTQDLDKVMSAVKGIDGVSVTSFSARTGNEEQT 180

Qy 181 RINLNCTQKALMQVVDFLSRNKQLYQKTEILSLEKPLLLHTGMGRLCTLDESVSLATMID 240
Db 181 RINLNCTQKALMQVVDFLSRNKQLYQKTEILSLEKPLLLHTGMGRLCTLDESVSLATMID 240

Qy 241 RIKRHLKLSHIRLALGVGRTLESQVKVVALCAGSGSSVLQGVEADLYLTGEMSHHDTLDA 300
Db 241 RIKRHLKLSHIRLALGVGRTLESQVKVVALCAGSGSSVLQGVEADLYLTGEMSHHDTLDA 300

Qy 301 ASQGINVILCEHSNTERGFLSDLRDMLDSHLENKINIILSETDRDPLQVV 350
Db 301 ASQGINVILCEHSNTERGFLSDLRDMLDSHLENKINIILSETDRDPLQVV 350

RESULT 2
AAB94573
ID AAB94573 standard; Protein; 350 AA.
XX
AC AAB94573;
XX
DT 26-JUN-2001 (first entry)
XX
DE Human protein sequence SEQ ID NO:15360.
XX
KW Human; primer; detection; diagnosis; antisense therapy; gene therapy.
XX
OS Homo sapiens.
XX
PN EP1074617-A2.
XX
PD 07-FEB-2001.
XX
PF 28-JUL-2000; 2000EP-0116126.
XX
PR 29-JUL-1999; 99JP-0248036.
PR 27-AUG-1999; 99JP-0300253.
PR 11-JAN-2000; 2000JP-0118776.
PR 02-MAY-2000; 2000JP-0183767.
PR 09-JUN-2000; 2000JP-0241899.
XX
PA (HELI-) HELIX RES INST.
XX
PI Ota T, Isogai T, Nishikawa T, Hayashi K, Saito K, Yamamoto J;
PI Ishii S, Sugiyama T, Wakamatsu A, Nagai K, Otsuki T;
XX
DR WPI; 2001-318749/34.
XX
PT Primer sets for synthesizing polynucleotides, particularly the 5602
PT full-length cDNAs defined in the specification, and for the detection
PT and/or diagnosis of the abnormality of the proteins encoded by the
PT full-length cDNAs -
XX
PS Claim 8; SEQ ID 15360; 2537pp + CD ROM; English.
XX
CC The present invention describes primer sets for synthesising 5602
CC full-length cDNAs defined in the specification. Where a primer set
CC comprises: (a) an oligo-dT primer and an oligonucleotide complementary
CC to the complementary strand of a polynucleotide which comprises one of
CC the 5602 nucleotide sequences defined in the specification, where the
CC oligonucleotide comprises at least 15 nucleotides; or (b) a combination
CC of an oligonucleotide comprising a sequence complementary to the
CC complementary strand of a polynucleotide which comprises a 5'-end
CC sequence and an oligonucleotide comprising a sequence complementary to a
CC polynucleotide which comprises a 3'-end sequence, where the
CC oligonucleotide comprises at least 15 nucleotides and the combination of
CC the 5'-end sequence/3'-end sequence is selected from those defined in
CC the specification. The primer sets can be used in antisense therapy and
CC in gene therapy. The primers are useful for synthesising polynucleotides,
CC particularly full-length cDNAs. The primers are also useful for the
CC detection and/or diagnosis of the abnormality of the proteins encoded by
CC the full-length cDNAs. The primers allow obtaining of the full-length
CC cDNAs easily without any specialised methods. AAH03166 to AAH13628 and
CC AAH13633 to AAH18742 represent human cDNA sequences; AAB92446 to
CC AAB95893 represent human amino acid sequences; and AAH13629 to AAH13632
CC represent oligonucleotides, all of which are used in the exemplification
CC of the present invention.
XX
SQ Sequence 350 AA;

Query Match 100.0%; Score 1799; DB 22; Length 350;
Best Local Similarity 100.0%; Pred. No. 1.4e-166;
Matches 350; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MDLKALLSSLNDFASLSFAESWDNVGLLVEPSPPHTVNTLFLTNDLTEEVMEEVLQKKAD 60
Db 1 MDLKALLSSLNDFASLSFAESWDNVGLLVEPSPPHTVNTLFLTNDLTEEVMEEVLQKKAD 60

Qy 61 LILSYHPPIFRPMKRITWNTWKERLVIRALENRVGIYSPHTAYDAAPQGVNNWLAKGLGA 120
Db 61 LILSYHPPIFRPMKRITWNTWKERLVIRALENRVGIYSPHTAYDAAPQGVNNWLAKGLGA 120

Qy 121 CTSRPIHPSKAPNYPTEGNHRVEFNVNYTQDLDKVMSAVKGIDGVSVTSFSARTGNEEQT 180
Db 121 CTSRPIHPSKAPNYPTEGNHRVEFNVNYTQDLDKVMSAVKGIDGVSVTSFSARTGNEEQT 180

Qy 181 RINLNCTQKALMQVVDFLSRNKQLYQKTEILSLEKPLLLHTGMGRLCTLDESVSLATMID 240
Db 181 RINLNCTQKALMQVVDFLSRNKQLYQKTEILSLEKPLLLHTGMGRLCTLDESVSLATMID 240

Qy 241 RIKRHLKLSHIRLALGVGRTLESQVKVVALCAGSGSSVLQGVEADLYLTGEMSHHDTLDA 300
Db 241 RIKRHLKLSHIRLALGVGRTLESQVKVVALCAGSGSSVLQGVEADLYLTGEMSHHDTLDA 300

Qy 301 ASQGINVILCEHSNTERGFLSDLRDMLDSHLENKINIILSETDRDPLQVV 350
Db 301 ASQGINVILCEHSNTERGFLSDLRDMLDSHLENKINIILSETDRDPLQVV 350

RESULT 3
AAM88085
ID AAM88085 standard; Protein; 383 AA.
XX
AC AAM88085;
XX

DT 07-NOV-2001 (first entry)
XX
DE Human immune/haematopoietic antigen SEQ ID NO:15678.
XX
KW Human; immune; haematopoietic; immune/haematopoietic antigen; cancer;
KW cytostatic; gene therapy; vaccine; metastasis.
XX
OS Homo sapiens.
XX
PN WO200157182-A2.
XX
PD 09-AUG-2001.
XX
PF 17-JAN-2001; 2001WO-US01354.
XX
PR 31-JAN-2000; 2000US-0179065.
PR 04-FEB-2000; 2000US-0180628.
PR 24-FEB-2000; 2000US-0184664.
PR 02-MAR-2000; 2000US-0186350.
PR 16-MAR-2000; 2000US-0189874.
PR 17-MAR-2000; 2000US-0190076.
PR 18-APR-2000; 2000US-0198123.
PR 19-MAY-2000; 2000US-0205515.
PR 07-JUN-2000; 2000US-0209467.
PR 28-JUN-2000; 2000US-0214886.
PR 30-JUN-2000; 2000US-0215135.
PR 07-JUL-2000; 2000US-0216647.
PR 07-JUL-2000; 2000US-0216880.
PR 11-JUL-2000; 2000US-0217487.
PR 11-JUL-2000; 2000US-0217496.
PR 14-JUL-2000; 2000US-0218290.
PR 26-JUL-2000; 2000US-0220963.
PR 26-JUL-2000; 2000US-0220964.
PR 14-AUG-2000; 2000US-0224518.
PR 14-AUG-2000; 2000US-0224519.
PR 14-AUG-2000; 2000US-0225213.
PR 14-AUG-2000; 2000US-0225214.
PR 14-AUG-2000; 2000US-0225266.
PR 14-AUG-2000; 2000US-0225267.
PR 14-AUG-2000; 2000US-0225268.
PR 14-AUG-2000; 2000US-0225270.
PR 14-AUG-2000; 2000US-0225447.
PR 14-AUG-2000; 2000US-0225757.
PR 14-AUG-2000; 2000US-0225758.
PR 14-AUG-2000; 2000US-0225759.
PR 18-AUG-2000; 2000US-0226279.
PR 22-AUG-2000; 2000US-0226681.
PR 22-AUG-2000; 2000US-0226868.
PR 22-AUG-2000; 2000US-0227182.
PR 23-AUG-2000; 2000US-0227009.
PR 30-AUG-2000; 2000US-0228924.
PR 01-SEP-2000; 2000US-0229287.
PR 01-SEP-2000; 2000US-0229343.
PR 01-SEP-2000; 2000US-0229344.
PR 01-SEP-2000; 2000US-0229345.
PR 05-SEP-2000; 2000US-0229509.
PR 05-SEP-2000; 2000US-0229513.
PR 06-SEP-2000; 2000US-0230437.
PR 06-SEP-2000; 2000US-0230438.
PR 08-SEP-2000; 2000US-0231242.
PR 08-SEP-2000; 2000US-0231243.
PR 08-SEP-2000; 2000US-0231244.
PR 08-SEP-2000; 2000US-0231413.
PR 08-SEP-2000; 2000US-0231414.
PR 08-SEP-2000; 2000US-0232080.
PR 08-SEP-2000; 2000US-0232081.
PR 12-SEP-2000; 2000US-0231968.
PR 14-SEP-2000; 2000US-0232397.
PR 14-SEP-2000; 2000US-0232398.
PR 14-SEP-2000; 2000US-0232399.
PR 14-SEP-2000; 2000US-0232400.
PR 14-SEP-2000; 2000US-0232401.
PR 14-SEP-2000; 2000US-0233063.
PR 14-SEP-2000; 2000US-0233064.
PR 14-SEP-2000; 2000US-0233065.
PR 21-SEP-2000; 2000US-0234223.
PR 21-SEP-2000; 2000US-0234274.
PR 25-SEP-2000; 2000US-0234997.
PR 25-SEP-2000; 2000US-0234998.
PR 26-SEP-2000; 2000US-0235484.
PR 27-SEP-2000; 2000US-0235834.
PR 27-SEP-2000; 2000US-0235836.
PR 29-SEP-2000; 2000US-0236327.
PR 29-SEP-2000; 2000US-0236367.
PR 29-SEP-2000; 2000US-0236368.
PR 29-SEP-2000; 2000US-0236369.
PR 29-SEP-2000; 2000US-0236370.
PR 02-OCT-2000; 2000US-0236802.
PR 02-OCT-2000; 2000US-0237037.
PR 02-OCT-2000; 2000US-0237038.
PR 02-OCT-2000; 2000US-0237039.
PR 02-OCT-2000; 2000US-0237040.
PR 13-OCT-2000; 2000US-0239935.
PR 13-OCT-2000; 2000US-0239937.
PR 20-OCT-2000; 2000US-0240960.
PR 20-OCT-2000; 2000US-0241221.
PR 20-OCT-2000; 2000US-0241785.
PR 20-OCT-2000; 2000US-0241786.
PR 20-OCT-2000; 2000US-0241787.
PR 20-OCT-2000; 2000US-0241808.
PR 20-OCT-2000; 2000US-0241809.
PR 20-OCT-2000; 2000US-0241826.
PR 01-NOV-2000; 2000US-0244617.
PR 08-NOV-2000; 2000US-0246474.
PR 08-NOV-2000; 2000US-0246475.
PR 08-NOV-2000; 2000US-0246476.
PR 08-NOV-2000; 2000US-0246477.
PR 08-NOV-2000; 2000US-0246478.
PR 08-NOV-2000; 2000US-0246523.
PR 08-NOV-2000; 2000US-0246524.
PR 08-NOV-2000; 2000US-0246525.
PR 08-NOV-2000; 2000US-0246526.
PR 08-NOV-2000; 2000US-0246527.
PR 08-NOV-2000; 2000US-0246528.
PR 08-NOV-2000; 2000US-0246532.
PR 08-NOV-2000; 2000US-0246609.
PR 08-NOV-2000; 2000US-0246610.
PR 08-NOV-2000; 2000US-0246611.
PR 08-NOV-2000; 2000US-0246613.
PR 17-NOV-2000; 2000US-0249207.
PR 17-NOV-2000; 2000US-0249208.
PR 17-NOV-2000; 2000US-0249209.
PR 17-NOV-2000; 2000US-0249210.
PR 17-NOV-2000; 2000US-0249211.
PR 17-NOV-2000; 2000US-0249212.
PR 17-NOV-2000; 2000US-0249213.
PR 17-NOV-2000; 2000US-0249214.
PR 17-NOV-2000; 2000US-0249215.
PR 17-NOV-2000; 2000US-0249216.
PR 17-NOV-2000; 2000US-0249217.
PR 17-NOV-2000; 2000US-0249218.
PR 17-NOV-2000; 2000US-0249244.
PR 17-NOV-2000; 2000US-0249245.
PR 17-NOV-2000; 2000US-0249264.
PR 17-NOV-2000; 2000US-0249265.
PR 17-NOV-2000; 2000US-0249297.
PR 17-NOV-2000; 2000US-0249299.
PR 17-NOV-2000; 2000US-0249300.
PR 01-DEC-2000; 2000US-0250160.
PR 01-DEC-2000; 2000US-0250391.
PR 05-DEC-2000; 2000US-0251030.
PR 05-DEC-2000; 2000US-0251988.
PR 05-DEC-2000; 2000US-0256719.
PR 06-DEC-2000; 2000US-0251479.
PR 08-DEC-2000; 2000US-0251856.
PR 08-DEC-2000; 2000US-0251868.

```
PR   08-DEC-2000; 2000US-0251869.
PR   08-DEC-2000; 2000US-0251989.
PR   08-DEC-2000; 2000US-0251990.
PR   11-DEC-2000; 2000US-0254097.
PR   05-JAN-2001; 2001US-0259678.
XX
PA   (HUMA-) HUMAN GENOME SCI INC.
XX
PI   Rosen CA,  Barash SC,  Ruben SM;
XX
DR   WPI; 2001-483426/52.
DR   N-PSDB; AAK60866.
XX
PT   Nucleic acids encoding human immune/hematopoietic antigen polypeptides,
PT   useful for preventing, diagnosing and/or treating cancers and
PT   metastasis -
XX
PS   Claim 11; SEQ ID NO 15678; 3071pp + Sequence Listing; English.
XX
CC   AAK54951 to AAK64702 encode the human immune/haematopoietic antigen (I)
CC   amino acid sequences given in AAM82170 to AAM91921. (I) have cytostatic
CC   activity, and can be used in gene therapy and vaccine production. (I)
CC   proteins and polynucleotides may be used in the prevention, diagnosis and
CC   treatment of diseases associated with inappropriate (I) expression. For
CC   example, they may be used to treat disorders associated with decreased
CC   expression by rectifying mutations or deletions in a patient's genome
CC   that affect the activity of (I) by expressing inactive proteins or to
CC   supplement the patients own production of (I). Additionally, (I)
CC   polynucleotides may be used to produce the secreted (I), by inserting
CC   the nucleic acids into a host cell and culturing the cell to express the
CC   protein. (I) proteins and polynucleotides may be used to prevent,
CC   diagnose and treat immune/haematopoietic-related diseases, especially
CC   cancers and cancer metastases of haematopoietic-derived cells. AAK64703
CC   to AAK87694 represent human immune/haematopoietic antigen genomic
CC   sequences from the present invention. AAK54942 to AAK54950 and AAM82169
CC   represent sequences used in the exemplification of the present invention.
XX
SQ   Sequence   383 AA;

  Query Match             100.0%;  Score 1799;  DB 22;  Length 383;
  Best Local Similarity   100.0%;  Pred. No. 1.6e-166;
  Matches  350;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MDLKALLSSLNDFASLSFAESWDNVGLLVEPSPPHTVNTLFLTNDLTEEVMEEVLQKKAD 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         34 MDLKALLSSLNDFASLSFAESWDNVGLLVEPSPPHTVNTLFLTNDLTEEVMEEVLQKKAD 93

Qy         61 LILSYHPPIFRPMKRITWNTWKERLVIRALENRVGIYSPHTAYDAAPQGVNNWLAKGLGA 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         94 LILSYHPPIFRPMKRITWNTWKERLVIRALENRVGIYSPHTAYDAAPQGVNNWLAKGLGA 153

Qy        121 CTSRPIHPSKAPNYPTEGNHRVEFNVNYTQDLDKVMSAVKGIDGVSVTSFSARTGNEEQT 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        154 CTSRPIHPSKAPNYPTEGNHRVEFNVNYTQDLDKVMSAVKGIDGVSVTSFSARTGNEEQT 213

Qy        181 RINLNCTQKALMQVVDFLSRNKQLYQKTEILSLEKPLLLHTGMGRLCTLDESVSLATMID 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        214 RINLNCTQKALMQVVDFLSRNKQLYQKTEILSLEKPLLLHTGMGRLCTLDESVSLATMID 273

Qy        241 RIKRHLKLSHIRLALGVGRTLESQVKVVALCAGSGSSVLQGVEADLYLTGEMSHHDTLDA 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        274 RIKRHLKLSHIRLALGVGRTLESQVKVVALCAGSGSSVLQGVEADLYLTGEMSHHDTLDA 333

Qy        301 ASQGINVILCEHSNTERGFLSDLRDMLDSHLENKINIILSETDRDPLQVV 350
              |||||||||||||||||||||||||||||||||||||||||||||||||
Db        334 ASQGINVILCEHSNTERGFLSDLRDMLDSHLENKINIILSETDRDPLQVV 383


RESULT 4
AAU27744
ID   AAU27744 standard; Protein; 377 AA.
XX
AC   AAU27744;
XX
DT   18-DEC-2001  (first entry)
XX
DE   Human full-length polypeptide sequence #69.
XX
KW   Mammal; human; rhesus monkey; baker's yeast; fission yeast; Norway rat;
KW   mouse; Chinese hamster; African clawed frog; fruit fly; dog; leukaemia;
KW   cancer; lymphoma; neuroblastoma; autoimmune disorder; cell proliferation;
KW   nervous system disorder; inflammatory disorder; cell differentiation;
KW   angiogenesis; stem cell growth factor; activin; inhibin; cartilage; burn;
KW   genetic disorder; bone regeneration; tendon; ligament; tissue repair;
KW   cytostatic; antirheumatic; antiarthritic; vulnerary; antiinflammatory;
KW   antibacterial; immunosuppressive; vasotropic; antiparkinsonian;
KW   neuroprotective; osteopathic; antidiabetic; antiasthmatic; antiallergic;
KW   immunostimulant; analgesic; gene therapy.
XX
OS   Homo sapiens.
XX
PN   WO200164834-A2.
XX
PD   07-SEP-2001.
XX
PF   26-FEB-2001; 2001WO-US04926.
XX
PR   28-FEB-2000; 2000US-0515126.
PR   18-MAY-2000; 2000US-0577409.
PR   17-JUN-2000; 2000US-0597707.
PR   14-JUL-2000; 2000US-0616807.
PR   19-SEP-2000; 2000US-0664641.
XX
PA   (HYSE-) HYSEQ INC.
XX
PI   Tang YT,  Liu C,  Zhou P,  Asundi V,  Zhang J,  Zhao QA,  Ren F;
PI   Xue AJ,  Yang Y,  Wehrman T,  Wang J,  Ma Y,  Wang D,  Chen R,  Xu C;
PI   Drmanac R;
XX
DR   WPI; 2001-589862/66.
DR   N-PSDB; AAS44644.
XX
PT   Novel polypeptides and nucleic acids obtained from cDNA libraries
PT   prepared from various human tissues, for diagnosis, treatment of
PT   cancer, neurological, inflammatory disorders and for use in arrays for
PT   detection -
XX
PS   Claim 10; SEQ ID No 241; 153pp; English.
XX
CC   Sequences AAU27676-AAU28019 represent full-length polypeptides and
CC   contig polypeptides of the invention. The proteins and their associated
CC   DNA sequences are useful for the treatment, diagnosis and prevention of
CC   various types of disorder in a mammalian subject such as a human, dog,
CC   monkey, mouse, hamster or rat. The disorders include cancers such as
CC   leukaemia, lymphoma and neuroblastoma, autoimmune disorders such as
CC   multiple sclerosis, connective tissue disease, rheumatoid arthritis,
CC   diabetes mellitus, allergic rhinitis, asthma and eczema, nervous system
CC   disorders such as Parkinson's disease, Alzheimer's disease, Huntington's
CC   chorea, amyotrophic lateral sclerosis, spinal muscular atrophy and
CC   Wernicke disease, inflammatory disorders such as nephritis, Crohn's
CC   disease, ischaemia-reperfusion injury, shock, sepsis and inflammatory
CC   bowel disease. The sequences exhibit activity relating to angiogenesis,
CC   cell proliferation, cell differentiation, stem cell growth factor,
CC   activin or inhibin. Therefore, they can be used to manipulate stem cells
CC   in culture to give rise to neuroepithelial cells that can be used to
CC   augment or replace cells damaged by illness, accidental damage or genetic
CC   disorders. The sequences may also be used for regeneration of bone,
CC   cartilage, tendons and ligaments and in tissue repair and burn healing.
CC   Note: Some sequences for this patent did not form part of the printed
CC   specification, but were obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence   377 AA;

  Query Match             99.7%;  Score 1793;  DB 22;  Length 377;
  Best Local Similarity   99.7%;  Pred. No. 6.1e-166;
```

```
  Matches  349;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy          1 MDLKALLSSLNDFASLSFAESWDNVGLLVEPSPPHTVNTLFLTNDLTEEVMEEVLQKKAD 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         28 MDLKALLSSLNDFASLSFAESWDNVGLLVEPSPPHTVNTLFLTNDLTEEVMEEVLQKKAD 87

Qy         61 LILSYHPPIFRPMKRITWNTWKERLVIRALENRVGIYSPHTAYDAAPQGVNNWLAKGLGA 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         88 LILSYHPPIFRPMKRITWNTWKERLVIRALENRVGIYSPHTAYDAAPQGVNNWLAKGLGA 147

Qy        121 CTSRPIHPSKAPNYPTEGNHRVEFNVNYTQDLDKVMSAVKGIDGVSVTSFSARTGNEEQT 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        148 CTSRPIHPSKAPNYPTEGNHRVEFNVNYTQDLDKVMSAVKGIDGVSVTSFSARTGNEEQT 207

Qy        181 RINLNCTQKALMQVVDFLSRNKQLYQKTEILSLEKPLLLHTGMGRLCTLDESVSLATMID 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        208 RINLNCTQKALMQVVDFLSRNKQLYQKTEILSLEKPLLLHTGMGRLCTLDESVSLATMID 267

Qy        241 RIKRHLKLSHIRLALGVGRTLESQVKVVALCAGSGSSVLQGVEADLYLTGEMSHHDTLDA 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||| |||
Db        268 RIKRHLKLSHIRLALGVGRTLESQVKVVALCAGSGSSVLQGVEADLYLTGEMSHHDILDA 327

Qy        301 ASQGINVILCEHSNTERGFLSDLRDMLDSHLENKINIILSETDRDPLQVV 350
              ||||||||||||||||||||||||||||||||||||||||||||||||||
Db        328 ASQGINVILCEHSNTERGFLSDLRDMLDSHLENKINIILSETDRDPLQVV 377


RESULT 5
AAB60663
ID   AAB60663 standard; Protein; 351 AA.
XX
AC   AAB60663;
XX
DT   04-MAY-2001  (first entry)
XX
DE   Human gene expression regulatory factor-related protein hNIF3-s.
XX
KW   Human gene expression regulatory factor-related protein; hNIF3-s;
KW   NGG1-interacting factor; haemopoietic stem cell; preparation;
KW   detection.
XX
OS   Homo sapiens.
XX
PN   CN1272543-A.
XX
PD   08-NOV-2000.
XX
PF   11-APR-2000; 2000CN-0115369.
XX
PR   11-APR-2000; 2000CN-0115369.
XX
PA   (NANF-) NANFANG RES CENT STATE HUMAN GENE GROUP.
XX
PI   Li N,  Xiao H,  Liu F;
XX
DR   WPI; 2001-183596/19.
DR   N-PSDB; AAF59945.
XX
PT   Human gene expression regulatory factor related protein and its coded
PT   sequence -
XX
PS   Claim 4; Page 19-20; 20pp; Chinese.
XX
CC   The invention relates to a novel human gene expression regulatory
CC   factor-related protein, hNIF3-s (NGG1-interacting factor, AAB60663),
CC   and cDNA encoding it (AAF59945). hNIF3-s is expressed in haemopoietic
CC   stem cells. The invention also relates to the preparation of hNIF3-s
CC   proteins and nucleic acids, and the detection of hNIF3-s proteins and
CC   nucleic acids in a sample. The present sequence represents hNIF3-s.
XX
SQ   Sequence   351 AA;

  Query Match             96.9%;  Score 1743.5;  DB 22;  Length 351;
  Best Local Similarity   98.0%;  Pred. No. 3.7e-161;
  Matches  344;  Conservative    2;  Mismatches    4;  Indels    1;  Gaps    1;

Qy          1 MDLKALLSSLNDFASLSFAESWDNVGLLVEPSPPHTVNTLFLTNDLTEEVMEEVLQKKAD 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MDLKALLSSLNDFASLSFAESWDNVGLLVEPSPPHTVNTLFLTNDLTEEVMEEVLQKKAD 60

Qy         61 LILSYHPPIFRPMKRITW-NTWKERLVIRALENRVGIYSPHTAYDAAPQGVNNWLAKGLG 119
              |||||||||||||||    :  :|||||||||||||||||||||||||||||||||||||
Db         61 LILSYHPPIFRPMKRINLEHMGRERLVIRALENRVGIYSPHTAYDAAPQGVNNWLAKGLG 120

Qy        120 ACTSRPIHPSKAPNYPTEGNHRVEFNVNYTQDLDKVMSAVKGIDGVSVTSFSARTGNEEQ 179
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 ACTSRPIHPSKAPNYPTEGNHRVEFNVNYTQDLDKVMSAVKGIDGVSVTSFSARTGNEEQ 180

Qy        180 TRINLNCTQKALMQVVDFLSRNKQLYQKTEILSLEKPLLLHTGMGRLCTLDESVSLATMI 239
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 TRINLNCTQKALMQVVDFLSRNKQLYQKTEILSLEKPLLLHTGMGRLCTLDESVSLATMI 240

Qy        240 DRIKRHLKLSHIRLALGVGRTLESQVKVVALCAGSGSSVLQGVEADLYLTGEMSHHDTLD 299
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 DRIKRHLKLSHIRLALGVGRTLESQVKVVALCAGSGSSVLQGVEADLYLTGEMSHHDTLD 300

Qy        300 AASQGINVILCEHSNTERGFLSDLRDMLDSHLENKINIILSETDRDPLQVV 350
              ||||||||||||||||||||||||||||||||||||||||||||||||||
Db        301 AASQGINVILCEHSNTERGFLSDLRDMLDSHLENKINIILSETDRDPLQVV 351


RESULT 6
ABB08182
ID   ABB08182 standard; Protein; 247 AA.
XX
AC   ABB08182;
XX
DT   23-SEP-2002  (first entry)
XX
DE   Human protein kinase C 27.17 polypeptide.
XX
KW   Human; protein kinase C 27.17; protein metabolism; enzyme.
XX
OS   Homo sapiens.
XX
PN   CN1333355-A.
XX
PD   30-JAN-2002.
XX
PF   07-JUL-2000; 2000CN-0117049.
XX
PR   07-JUL-2000; 2000CN-0117049.
XX
PA   (SHAN-) SHANGHAI BIODOOR GENE DEV CO LTD.
XX
PI   Mao Y,  Xie Y;
XX
DR   WPI; 2002-305609/35.
DR   N-PSDB; ABL60919.
XX
PT   Human protein kinase C 27.17 polypeptide and its encoding
PT   polynucleotide, for treating e.g. protein metabolism disturbance -
XX
PS   Claim 1; Page 26-27 (disclosure); 33pp; Chinese.
XX
CC   The invention relates to a human protein kinase C 27.17 polypeptide and
CC   its encoding polynucleotide. The polypeptide can be expressed by standard
CC   DNA recombination. The polynucleotide, polypeptide and its antagonist are
CC   useful for treating e.g. protein metabolism disturbance. The present
CC   sequence represents the human protein kinase C 27.17 polypeptide.
XX
SQ   Sequence   247 AA;

  Query Match             61.0%;  Score 1097;  DB 23;  Length 247;
  Best Local Similarity   93.7%;  Pred. No. 2.5e-98;
  Matches  224;  Conservative    2;  Mismatches    9;  Indels    4;  Gaps    3;
```

```
Qy        113 WLAKGLGACTSRPIHPS-KAPNYPTEGNHRVEFNVNYTQDLDKVMSAVKGIDGVSVTSFS 171
              || |||      | | | :|||:|  | ||||||||||||||||||||||||||||||||
Db         12 WL-KGLELVP--PGHTSFQAPNFPYRGTHRVEFNVNYTQDLDKVMSAVKGIDGVSVTSFS 68

Qy        172 ARTGNEEQTRINLNCTQKALMQVVDFLSRNKQLYQKTEILSLEKPLLLHTGMGRLCTLDE 231
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         69 ARTGNEEQTRINLNCTQKALMQVVDFLSRNKQLYQKTEILSLEKPLLLHTGMGRLCTLDE 128

Qy        232 SVSLATMIDRIKRHLKLSHIRLALGVGRTLESQVKVVALCAGSGSSVLQGVEADLYLTGE 291
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        129 SVSLATMIDRIKRHLKLSHIRLALGVGRTLESQVKVVALCAGSGSSVLQGVEADLYLTGE 188

Qy        292 MSHHDTLDAASQGINVILCEHSNTERGFLSDLRDMLDSHLENKINIILSETDRDPLQVV 350
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        189 MSHHDTLDAASQGINVILCEHSNTERGFLSDLRDMLDSHLENKINIILSETDRDPLQVV 247
```

RESULT 7
ABB60530
ID ABB60530 standard; Protein; 288 AA.
XX
AC ABB60530;
XX
DT 26-MAR-2002 (first entry)
XX
DE Drosophila melanogaster polypeptide SEQ ID NO 8382.
XX
KW Drosophila; developmental biology; cell signalling; insecticide;
KW pharmaceutical.
XX
OS Drosophila melanogaster.
XX
PN WO200171042-A2.
XX
PD 27-SEP-2001.
XX
PF 23-MAR-2001; 2001WO-US09231.
XX
PR 23-MAR-2000; 2000US-191637P.
PR 11-JUL-2000; 2000US-0614150.
XX
PA (PEKE) PE CORP NY.
XX
PI Venter JC, Adams M, Li PWD, Myers EW;
XX
DR WPI; 2001-656860/75.
DR N-PSDB; ABL04633.
XX
PT New isolated nucleic acid detection reagent for detecting 1000 or more
PT genes from Drosophila and for elucidating cell signalling and cell-cell
PT interactions -
XX
PS Disclosure; SEQ ID NO 8382; 21pp + Sequence Listing; English.
XX
CC The invention relates to an isolated nucleic acid detection reagent
CC capable of detecting 1000 or more genes from Drosophila. The invention is
CC useful in developmental biology and in elucidating cell signalling and
CC cell-cell interactions in higher eukaryotes for the development of
CC insecticides, therapeutics and pharmaceutical drugs. The invention
CC discloses genomic DNA sequences (ABL16176-ABL30511), expressed DNA
CC sequences (ABL01840-ABL16175) and the encoded proteins
CC (ABB57737-ABB72072).
CC The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 288 AA;

  Query Match   32.1%; Score 578; DB 22; Length 288;
  Best Local Similarity 33.9%; Pred. No. 1.4e-47;
  Matches 118; Conservative   61; Mismatches   81; Indels   88; Gaps   4;

```
Qy          3 LKALLSSLNDFASLSFAESWDNVGLLVEPSPPHTVNTLFLTNDLTEEVMEEVLQKKADLI 62
              | |::  | :||  |:|| |||||||:||     :  : ||||||| |::| |:|:|:||
Db          9 LAAVVKELENFAPTSWAEKWDNVGLLIEPHREKQIKKILLTNDLTEPVVKEALEKEAELI 68

Qy         63 LSYHPPIFRPMKRITWNTWKERLVIRALENRVGIYSPHTAYDAAPQGVNNWLAKGLGACT 122
              :|||||||:|: ||| : |||:|   | | : :||||||:|    |||:||:| :   :
Db         69 ISYHPPIFKPLTRITQSHWKERVVAACLANDIALYSPHTAWDKKSGGVNDWLSKAVNIIS 128

Qy        123 SRPIHPSKAPNYPTEGNHRVEFNVNYTQDLDKVMSAVKGIDGVSVTSFSARTGNEEQTRI 182
              ||: |                          : |  |
Db        129 IRPLEPE-------------------------LGAPPG--------------------- 141

Qy        183 NLNCTQKALMQVVDFLSRNKQLYQKTEILSLEKPLLLHTGMGRLCTLDESVSLATMIDRI 242
                                                || ||   ::  : |: ::: :
Db        142 ------------------------------------TGSGRY--IETKMELSQVVESL 161

Qy        243 KRHLKLSHIRLALGVGRTLESQVKVVALCAGSGSSVLQGVEADLYLTGEMSHHDTLDAAS 302
              :: :: | : :|| || | :: :: | :|||||:|:|:|::||| :|||||||: |:
Db        162 QKRIRNS-VHVALAVGHTPKTLIQSVGICAGSGASLLKGIQADLIITGEMSHHEVLEFTH 220

Qy        303 QGINVILCEHSNTERGFLSDLRDMLDSHLENKINIILSETDRDPLQVV 350
                |:|| |||:||||| :   :|   |  :  : :|| |:|||  |
Db        221 NNTTVLLCNHSNSERGFLHEFCPILAKSLNEECLVFVSEVDKDPLVTV 268
```

RESULT 8
AAU27916
ID AAU27916 standard; Protein; 146 AA.
XX
AC AAU27916;
XX
DT 18-DEC-2001 (first entry)
XX
DE Human contig polypeptide sequence #69.
XX
KW Mammal; human; rhesus monkey; baker's yeast; fission yeast; Norway rat;
KW mouse; Chinese hamster; African clawed frog; fruit fly; dog; leukaemia;
KW cancer; lymphoma; neuroblastoma; autoimmune disorder; cell proliferation;
KW nervous system disorder; inflammatory disorder; cell differentiation;
KW angiogenesis; stem cell growth factor; activin; inhibin; cartilage; burn;
KW genetic disorder; bone regeneration; tendon; ligament; tissue repair;
KW cytostatic; antirheumatic; antiarthritic; vulnerary; antiinflammatory;
KW antibacterial; immunosuppressive; vasotropic; antiparkinsonian;
KW neuroprotective; osteopathic; antidiabetic; antiasthmatic; antiallergic;
KW immunostimulant; analgesic; gene therapy.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO200164834-A2.
XX
PD 07-SEP-2001.
XX
PF 26-FEB-2001; 2001WO-US04926.
XX
PR 28-FEB-2000; 2000US-0515126.
PR 18-MAY-2000; 2000US-0577409.
PR 17-JUN-2000; 2000US-0597707.
PR 14-JUL-2000; 2000US-0616807.
PR 19-SEP-2000; 2000US-0664641.
XX
PA (HYSE-) HYSEQ INC.
XX
PI Tang YT, Liu C, Zhou P, Asundi V, Zhang J, Zhao QA, Ren F;
PI Xue AJ, Yang Y, Wehrman T, Wang J, Ma Y, Wang D, Chen R, Xu C;
PI Drmanac R;
XX
DR WPI; 2001-589862/66.
DR N-PSDB; AAS44816.
XX
PT Novel polypeptides and nucleic acids obtained from cDNA libraries
PT prepared from various human tissues, for diagnosis, treatment of
PT cancer, neurological, inflammatory disorders and for use in arrays for

```
PT   detection  -
XX
PS   Claim 10; Page 132; 153pp; English.
XX
CC   Sequences AAU27676-AAU28019 represent full-length polypeptides and
CC   contig polypeptides of the invention. The proteins and their associated
CC   DNA sequences are useful for the treatment, diagnosis and prevention of
CC   various types of disorder in a mammalian subject such as a human, dog,
CC   monkey, mouse, hamster or rat. The disorders include cancers such as
CC   leukaemia, lymphoma and neuroblastoma, autoimmune disorders such as
CC   multiple sclerosis, connective tissue disease, rheumatoid arthritis,
CC   diabetes mellitus, allergic rhinitis, asthma and eczema, nervous system
CC   disorders such as Parkinson's disease, Alzheimer's disease, Huntington's
CC   chorea, amyotrophic lateral sclerosis, spinal muscular atrophy and
CC   Wernicke disease, inflammatory disorders such as nephritis, Crohn's
CC   disease, ischaemia-reperfusion injury, shock, sepsis and inflammatory
CC   bowel disease. The sequences exhibit activity relating to angiogenesis,
CC   cell proliferation, cell differentiation, stem cell growth factor,
CC   activin or inhibin. Therefore, they can be used to manipulate stem cells
CC   in culture to give rise to neuroepithelial cells that can be used to
CC   augment or replace cells damaged by illness, accidental damage or genetic
CC   disorders. The sequences may also be used for regeneration of bone,
CC   cartilage, tendons and ligaments and in tissue repair and burn healing.
CC   Note: Some sequences for this patent did not form part of the printed
CC   specification, but were obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence   146 AA;

  Query Match             29.8%;  Score 536;  DB 22;  Length 146;
  Best Local Similarity   88.7%;  Pred. No. 5.7e-44;
  Matches  102;  Conservative    6;  Mismatches    7;  Indels    0;  Gaps    0;

Qy          1 MDLKALLSSLNDFASLSFAESWDNVGLLVEPSPPHTVNTLFLTNDLTEEVMEEVLQKKAD 60
              || :|||||||||||||||||||||||||||||||||||||||||||||:|||:||| |||
Db         32 MDWRALLSSLNDFASLSFAESWDNVGLLVEPSPPHTVNTLFLTNDLTDEVMDEVLLKKAH 91

Qy         61 LILSYHPPIFRPMKRITWNTWKERLVIRALENRVGIYSPHTAYDAAPQGVNNWLA 115
              ||||||| |||||||||||||| ||||||||||||||:|  :|||||||||:|
Db         92 LILSYHPSIFRPMKRITWNTWKELLVIRALENRVGIYSPYTTXEAAPQGVNNWVA 146


RESULT 9
ABG20985
ID   ABG20985 standard; Protein; 110 AA.
XX
AC   ABG20985;
XX
DT   18-FEB-2002  (first entry)
XX
DE   Novel human diagnostic protein #20976.
XX
KW   Human; chromosome mapping; gene mapping; gene therapy; forensic;
KW   food supplement; medical imaging; diagnostic; genetic disorder.
XX
OS   Homo sapiens.
XX
PN   WO200175067-A2.
XX
PD   11-OCT-2001.
XX
PF   30-MAR-2001; 2001WO-US08631.
XX
PR   31-MAR-2000; 2000US-0540217.
PR   23-AUG-2000; 2000US-0649167.
XX
PA   (HYSE-) HYSEQ INC.
XX
PI   Drmanac RT,  Liu C,  Tang YT;
XX
DR   WPI; 2001-639362/73.
DR   N-PSDB; AAS85172.
XX
PT   New isolated polynucleotide and encoded polypeptides, useful in
PT   diagnostics, forensics, gene mapping, identification of mutations
PT   responsible for genetic disorders or other traits and to assess
PT   biodiversity  -
XX
PS   Claim 20; SEQ ID No 51344; 103pp; English.
XX
CC   The invention relates to isolated polynucleotide (I) and
CC   polypeptide (II) sequences. (I) is useful as hybridisation probes,
CC   polymerase chain reaction (PCR) primers, oligomers, and for chromosome
CC   and gene mapping, and in recombinant production of (II). The
CC   polynucleotides are also used in diagnostics as expressed sequence tags
CC   for identifying expressed genes. (I) is useful in gene therapy techniques
CC   to restore normal activity of (II) or to treat disease states involving
CC   (II). (II) is useful for generating antibodies against it, detecting or
CC   quantitating a polypeptide in tissue, as molecular weight markers and as
CC   a food supplement. (II) and its binding partners are useful in medical
CC   imaging of sites expressing (II). (I) and (II) are useful for treating
CC   disorders involving aberrant protein expression or biological activity.
CC   The polypeptide and polynucleotide sequences have applications in
CC   diagnostics, forensics, gene mapping, identification of mutations
CC   responsible for genetic disorders or other traits to assess biodiversity
CC   and to produce other types of data and products dependent on DNA and
CC   amino acid sequences. ABG00010-ABG30377 represent novel human
CC   diagnostic amino acid sequences of the invention.
CC   Note: The sequence data for this patent did not appear in the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence   110 AA;

  Query Match             28.2%;  Score 508;  DB 22;  Length 110;
  Best Local Similarity   100.0%;  Pred. No. 2e-41;
  Matches  102;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        174 TGNEEQTRINLNCTQKALMQVVDFLSRNKQLYQKTEILSLEKPLLLHTGMGRLCTLDESV 233
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          2 TGNEEQTRINLNCTQKALMQVVDFLSRNKQLYQKTEILSLEKPLLLHTGMGRLCTLDESV 61

Qy        234 SLATMIDRIKRHLKLSHIRLALGVGRTLESQVKVVALCAGSG 275
              |||||||||||||||||||||||||||||||||||||||||||
Db         62 SLATMIDRIKRHLKLSHIRLALGVGRTLESQVKVVALCAGSG 103


RESULT 10
ABG52473
ID   ABG52473 standard; Peptide; 68 AA.
XX
AC   ABG52473;
XX
DT   25-FEB-2003  (first entry)
XX
DE   Human liver peptide, SEQ ID No 31121.
XX
KW   Human; liver; cirrhosis; hyperlipoproteinaemia; hyperlipidaemia;
KW   hypercholesterolaemia; coronary heart disease.
XX
OS   Homo sapiens.
XX
PN   WO200157273-A2.
XX
PD   09-AUG-2001.
XX
PF   30-JAN-2001; 2001WO-US00664.
XX
PR   04-FEB-2000; 2000US-0180312.
PR   26-MAY-2000; 2000US-0207456.
PR   30-JUN-2000; 2000US-0608408.
PR   03-AUG-2000; 2000US-0632366.
PR   21-SEP-2000; 2000US-0234687.
PR   27-SEP-2000; 2000US-0236359.
PR   04-OCT-2000; 2000GB-0024263.
XX
```

```
PA   (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI   Penn SG,  Hanzel DK,  Chen W,  Rank DR;
XX
DR   WPI; 2001-488898/53.
XX
PT   Human genome-derived single exon nucleic acid probes useful for
PT   analysing gene expression in human adult liver -
XX
PS   Claim 27; SEQ ID No 31121; 658pp; English.
XX
CC   The invention relates to a single exon nucleic acid probe (SENP) (I) for
CC   measuring human gene expression in a sample derived from human adult
CC   liver, comprising one of 13109 defined nucleotide sequences given in the
CC   specification (or complements/ fragments). The probe hybridises at high
CC   stringency to a nucleic acid molecule expressed in the human adult
CC   liver. (I) may be used for predicting, measuring and displaying gene
CC   expression in samples derived from human adult liver. The genes
CC   identified may be involved in genetic liver diseases such as cirrhosis,
CC   hyperlipoproteinaemia, hyperlipidaemia and hypercholesterolaemia which
CC   is associated with coronary heart disease. ABG47348-ABG59930 represent
CC   human liver single exon encoded peptides of the invention.
CC   Note: The sequence information for this patent does not appear in the
CC   printed specification but was obtained in electronic format directly
CC   from WIPO at ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence   68 AA;

  Query Match             20.3%;  Score 366;  DB 22;  Length 68;
  Best Local Similarity   100.0%;  Pred. No. 6.5e-28;
  Matches   68;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         51 MEEVLQKKADLILSYHPPIFRPMKRITWNTWKERLVIRALENRVGIYSPHTAYDAAPQGV 110
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MEEVLQKKADLILSYHPPIFRPMKRITWNTWKERLVIRALENRVGIYSPHTAYDAAPQGV 60

Qy        111 NNWLAKGL 118
              ||||||||
Db         61 NNWLAKGL 68


RESULT 11
ABB32385
ID   ABB32385 standard; Peptide; 68 AA.
XX
AC   ABB32385;
XX
DT   01-FEB-2002  (first entry)
XX
DE   Peptide #5036 encoded by breast cell single exon nucleic acid probe.
XX
KW   Human; microarray; single exon probe; gene expression; breast;
KW   disease; cancer.
XX
OS   Homo sapiens.
XX
PN   WO200157271-A2.
XX
PD   09-AUG-2001.
XX
PF   30-JAN-2001; 2001WO-US00662.
XX
PR   04-FEB-2000; 2000US-0180312.
PR   26-MAY-2000; 2000US-0207456.
PR   30-JUN-2000; 2000US-0608408.
PR   03-AUG-2000; 2000US-0632366.
PR   21-SEP-2000; 2000US-0234687.
PR   27-SEP-2000; 2000US-0236359.
PR   04-OCT-2000; 2000GB-0024263.
XX
PA   (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI   Penn SG,  Hanzel DK,  Chen W,  Rank DR;
XX
DR   WPI; 2001-496933/54.
XX
PT   New spatially-addressable set of single exon nucleic acid probes,
PT   useful for measuring gene expression in sample derived from human
PT   breast, comprises number of single exon nucleic acid probes  -
XX
PS   Claim 27; SEQ ID NO 15353; 327pp + sequence listing; English.
XX
CC   The invention relates to a spatially-addressable set of single exon
CC   nucleic acid probes for measuring gene expression in a sample derived
CC   from human breast and BT 474 cells. The method involves contacting
CC   the probes with a collection of detectably labelled nucleic acids
CC   derived from mRNA of human breast, and then measuring the label
CC   bound to each probe of the microarray. The probes are useful for
CC   verifying the expression of regions of genomic DNA predicted to
CC   encode proteins. They are useful for gene discovery, and for
CC   determining predisposition and/or prognosing breast disease. Gene
CC   expression analysis is useful for assessing the toxicity of chemical
CC   agents on cells. The microarray of this invention presents a far greater
CC   diversity of probes for measuring gene expression, with far less bias
CC   than expressed sequence tag microarrays. The method is suitable for
CC   rapid production of functional information from genomic sequence. The
CC   present sequence is a peptide encoded by a single exon nucleic acid
CC   probe of the invention.
CC   Note: The sequence data for this patent did not form part of the
CC   printed specification, but was obtained in electronic format directly
CC   from WIPO at ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence   68 AA;

  Query Match             20.3%;  Score 366;  DB 22;  Length 68;
  Best Local Similarity   100.0%;  Pred. No. 6.5e-28;
  Matches   68;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         51 MEEVLQKKADLILSYHPPIFRPMKRITWNTWKERLVIRALENRVGIYSPHTAYDAAPQGV 110
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MEEVLQKKADLILSYHPPIFRPMKRITWNTWKERLVIRALENRVGIYSPHTAYDAAPQGV 60

Qy        111 NNWLAKGL 118
              ||||||||
Db         61 NNWLAKGL 68


RESULT 12
ABB37667
ID   ABB37667 standard; Peptide; 68 AA.
XX
AC   ABB37667;
XX
DT   04-FEB-2002  (first entry)
XX
DE   Peptide #5173 encoded by human foetal liver single exon probe.
XX
KW   Human; foetal liver; gene expression; single exon nucleic acid probe.
XX
OS   Homo sapiens.
XX
PN   WO200157277-A2.
XX
PD   09-AUG-2001.
XX
PF   30-JAN-2001; 2001WO-US00669.
XX
PR   04-FEB-2000; 2000US-0180312.
PR   26-MAY-2000; 2000US-0207456.
PR   30-JUN-2000; 2000US-0608408.
PR   03-AUG-2000; 2000US-0632366.
PR   21-SEP-2000; 2000US-0234687.
PR   27-SEP-2000; 2000US-0236359.
PR   04-OCT-2000; 2000GB-0024263.
XX
PA   (MOLE-) MOLECULAR DYNAMICS INC.
```

```
XX
PI   Penn SG,  Hanzel DK,  Chen W,  Rank DR;
XX
DR   WPI; 2001-483447/52.
XX
PT   Human genome-derived single exon nucleic acid probes useful for
PT   analyzing gene expression in human fetal liver -
XX
PS   Claim 27; SEQ ID NO 30302; 639pp + sequence listing; English.
XX
CC   The invention relates to a single exon nucleic acid probe for
CC   measuring human gene expression in a sample derived from human foetal
CC   liver. The single exon nucleic acid probes may be used for predicting,
CC   measuring and displaying gene expression in samples derived from human
CC   fetal liver. The present sequence is a peptide encoded by a single exon
CC   nucleic acid probe of the invention.
CC   Note: The sequence data for this patent did not form part of the
CC   printed specification, but was obtained in electronic format directly
CC   from WIPO at ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence   68 AA;

  Query Match             20.3%;  Score 366;  DB 22;  Length 68;
  Best Local Similarity   100.0%;  Pred. No. 6.5e-28;
  Matches   68;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         51 MEEVLQKKADLILSYHPPIFRPMKRITWNTWKERLVIRALENRVGIYSPHTAYDAAPQGV 110
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MEEVLQKKADLILSYHPPIFRPMKRITWNTWKERLVIRALENRVGIYSPHTAYDAAPQGV 60

Qy        111 NNWLAKGL 118
              ||||||||
Db         61 NNWLAKGL 68


RESULT 13
AAM58295
ID   AAM58295 standard; Protein; 68 AA.
XX
AC   AAM58295;
XX
DT   05-NOV-2001  (first entry)
XX
DE   Human brain expressed single exon probe encoded protein SEQ ID NO: 30400.
XX
KW   Human; brain expressed exon; gene expression analysis; probe;
KW   microarray; Alzheimer's disease; multiple sclerosis; schizophrenia;
KW   epilepsy; cancer.
XX
OS   Homo sapiens.
XX
PN   WO200157275-A2.
XX
PD   09-AUG-2001.
XX
PF   30-JAN-2001; 2001WO-US00667.
XX
PR   04-FEB-2000; 2000US-0180312.
PR   26-MAY-2000; 2000US-0207456.
PR   30-JUN-2000; 2000US-0608408.
PR   03-AUG-2000; 2000US-0632366.
PR   21-SEP-2000; 2000US-0234687.
PR   27-SEP-2000; 2000US-0236359.
PR   04-OCT-2000; 2000GB-0024263.
XX
PA   (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI   Penn SG,  Hanzel DK,  Chen W,  Rank DR;
XX
DR   WPI; 2001-483446/52.
XX
PT   Single exon nucleic acid probes for analyzing gene expression in human
PT   brains -
XX
PS   Example 4; SEQ ID NO: 30400; 650pp + Sequence Listing; English.
XX
CC   The present invention provides a number of single exon nucleic acid
CC   probes which are derived from genomic sequences expressed in the human
CC   brain. They can be used to measure gene expression in brain cell samples,
CC   which may enable the diagnosis and improved treatment of nervous system
CC   diseases such as Alzheimer's disease, multiple sclerosis, schizophrenia,
CC   epilepsy and cancers. The present sequence is a protein encoded by one of
CC   the probes of the invention.
XX
SQ   Sequence   68 AA;

  Query Match             20.3%;  Score 366;  DB 22;  Length 68;
  Best Local Similarity   100.0%;  Pred. No. 6.5e-28;
  Matches   68;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         51 MEEVLQKKADLILSYHPPIFRPMKRITWNTWKERLVIRALENRVGIYSPHTAYDAAPQGV 110
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MEEVLQKKADLILSYHPPIFRPMKRITWNTWKERLVIRALENRVGIYSPHTAYDAAPQGV 60

Qy        111 NNWLAKGL 118
              ||||||||
Db         61 NNWLAKGL 68


RESULT 14
AAM18609
ID   AAM18609 standard; Protein; 68 AA.
XX
AC   AAM18609;
XX
DT   12-OCT-2001  (first entry)
XX
DE   Peptide #5043 encoded by probe for measuring cervical gene expression.
XX
KW   Probe; human; microarray; gene expression; cervical epithelial cell;
KW   cervical cancer.
XX
OS   Homo sapiens.
XX
PN   WO200157278-A2.
XX
PD   09-AUG-2001.
XX
PF   30-JAN-2001; 2001WO-US00670.
XX
PR   04-FEB-2000; 2000US-0180312.
PR   26-MAY-2000; 2000US-0207456.
PR   30-JUN-2000; 2000US-0608408.
PR   03-AUG-2000; 2000US-0632366.
PR   21-SEP-2000; 2000US-0234687.
PR   27-SEP-2000; 2000US-0236359.
PR   04-OCT-2000; 2000GB-0024263.
XX
PA   (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI   Penn SG,  Hanzel DK,  Chen W,  Rank DR;
XX
DR   WPI; 2001-488901/53.
XX
PT   Human genome-derived single exon nucleic acid probes useful for
PT   analyzing gene expression in human cervical epithelial cells -
XX
PS   Claim 27; SEQ ID No 23435; 487pp; English.
XX
CC   The present invention relates to human single exon nucleic acid probes
CC   (SENP: see AAI10068-AAI28459). The present sequence is a peptide encoded
CC   by one such probe. The SENPs are derived from human HeLa cells. The SENPs
CC   can be used to produce a single exon microarray, which can be used for
CC   measuring human gene expression in a sample derived from human cervical
CC   epithelial cells. By measuring gene expression, the probes are therefore
CC   useful in grading and/or staging of diseases of the cervix, notably
```

```
CC   cervical cancer.
CC   Note: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence   68 AA;

  Query Match             20.3%;  Score 366;  DB 22;  Length 68;
  Best Local Similarity   100.0%;  Pred. No. 6.5e-28;
  Matches   68;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         51 MEEVLQKKADLILSYHPPIFRPMKRITWNTWKERLVIRALENRVGIYSPHTAYDAAPQGV 110
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MEEVLQKKADLILSYHPPIFRPMKRITWNTWKERLVIRALENRVGIYSPHTAYDAAPQGV 60

Qy        111 NNWLAKGL 118
              ||||||||
Db         61 NNWLAKGL 68


RESULT 15
AAM06178
ID   AAM06178 standard; Protein; 68 AA.
XX
AC   AAM06178;
XX
DT   09-OCT-2001  (first entry)
XX
DE   Peptide #4860 encoded by probe for measuring breast gene expression.
XX
KW   Probe; human; breast disease; breast cancer; development disorder;
KW   inflammatory disease; proliferative breast disease; non-carcinoma tumour.
XX
OS   Homo sapiens.
XX
PN   WO200157270-A2.
XX
PD   09-AUG-2001.
XX
PF   29-JAN-2001; 2001WO-US00661.
XX
PR   04-FEB-2000; 2000US-0180312.
PR   26-MAY-2000; 2000US-0207456.
PR   30-JUN-2000; 2000US-0608408.
PR   03-AUG-2000; 2000US-0632366.
PR   21-SEP-2000; 2000US-0234687.
PR   27-SEP-2000; 2000US-0236359.
PR   04-OCT-2000; 2000GB-0024263.
XX
PA   (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI   Penn SG,  Hanzel DK,  Chen W,  Rank DR;
XX
DR   WPI; 2001-476286/51.
XX
PT   Novel single exon nucleic acid probe used to measuring gene expression
PT   in a human breast -
XX
PS   Claim 27; SEQ ID No 14918; 322pp; English.
XX
CC   The present invention relates to novel single exon nucleic acid probes
CC   (see AAI00010-AAI10067). The present sequence is a peptide encoded by one
CC   such probe. The probes are useful for measuring human gene expression in
CC   a human breast sample, where the probe hybridises at high stringency to a
CC   nucleic acid expressed in the human breast. The probes are useful for
CC   predicting, diagnosing, grading, staging, monitoring and prognosing
CC   diseases of the human breast, particularly those diseases with polygenic
CC   aetiology. The diseases include: breast cancer, disorders of development,
CC   inflammatory diseases of the breast, fibrocystic changes, proliferative
CC   breast disease and non-carcinoma tumours.
CC   Note: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence   68 AA;

  Query Match             20.3%;  Score 366;  DB 22;  Length 68;
  Best Local Similarity   100.0%;  Pred. No. 6.5e-28;
  Matches   68;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         51 MEEVLQKKADLILSYHPPIFRPMKRITWNTWKERLVIRALENRVGIYSPHTAYDAAPQGV 110
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MEEVLQKKADLILSYHPPIFRPMKRITWNTWKERLVIRALENRVGIYSPHTAYDAAPQGV 60

Qy        111 NNWLAKGL 118
              ||||||||
Db         61 NNWLAKGL 68


Search completed: August 22, 2003, 15:03:40
Job time : 91 secs
```